153 related articles for article (PubMed ID: 32138466)
1. G Protein-Coupled Receptor 30 Mediates the Anticancer Effects Induced by Eicosapentaenoic Acid in Ovarian Cancer Cells.
Zhao Y; Zhao MF; Yang ML; Wu TY; Xu CJ; Wang JM; Li CJ; Li X
Cancer Res Treat; 2020 Jul; 52(3):815-829. PubMed ID: 32138466
[TBL] [Abstract][Full Text] [Related]
2. Low Doses of Nonylphenol Promote Growth of Colon Cancer Cells through Activation of ERK1/2 via G Protein‒Coupled Receptor 30.
Xie M; Liang JL; Huang HD; Wang MJ; Zhang T; Yang XF
Cancer Res Treat; 2019 Oct; 51(4):1620-1631. PubMed ID: 31096733
[TBL] [Abstract][Full Text] [Related]
3. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
[TBL] [Abstract][Full Text] [Related]
4. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.
Lam HM; Ouyang B; Chen J; Ying J; Wang J; Wu CL; Jia L; Medvedovic M; Vessella RL; Ho SM
Endocr Relat Cancer; 2014; 21(6):903-14. PubMed ID: 25287069
[TBL] [Abstract][Full Text] [Related]
5. Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression.
Long L; Cao Y; Tang LD
Int J Gynecol Cancer; 2012 May; 22(4):539-45. PubMed ID: 22495744
[TBL] [Abstract][Full Text] [Related]
6. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo.
Wei W; Chen ZJ; Zhang KS; Yang XL; Wu YM; Chen XH; Huang HB; Liu HL; Cai SH; Du J; Wang HS
Cell Death Dis; 2014 Oct; 5(10):e1428. PubMed ID: 25275589
[TBL] [Abstract][Full Text] [Related]
7. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
9. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.
Chan QK; Lam HM; Ng CF; Lee AY; Chan ES; Ng HK; Ho SM; Lau KM
Cell Death Differ; 2010 Sep; 17(9):1511-23. PubMed ID: 20203690
[TBL] [Abstract][Full Text] [Related]
10. Docosahexaenoic Acid Induces Growth Suppression on Epithelial Ovarian Cancer Cells More Effectively than Eicosapentaenoic Acid.
Wan XH; Fu X; Ababaikeli G
Nutr Cancer; 2016; 68(2):320-7. PubMed ID: 26942868
[TBL] [Abstract][Full Text] [Related]
11. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid induced SKOV-3 cell apoptosis through ERK1/2-mTOR-NF-κB pathways.
Han L; Zhang Y; Meng M; Cheng D; Wang C
Anticancer Drugs; 2016 Aug; 27(7):635-42. PubMed ID: 27176035
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumorigenic action of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b)pyran: evidence for involvement of GPR30/EGFR signaling pathway.
Chandra V; Fatima I; Saxena R; Hussain MK; Hajela K; Sankhwar P; Roy BG; Chandna S; Dwivedi A
Gynecol Oncol; 2013 May; 129(2):433-42. PubMed ID: 23402905
[TBL] [Abstract][Full Text] [Related]
14. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
15. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
16. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.
Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X
Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265
[TBL] [Abstract][Full Text] [Related]
17. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M
PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246
[TBL] [Abstract][Full Text] [Related]
18. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
[TBL] [Abstract][Full Text] [Related]
19. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
20. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
